PGLYRP4 and pertussis: Strikingly, PGLYRP4 has been shown to contribute to sphingosine-1-phosphate receptor (S1PR) agonist-mediated disease attenuation during Bordetella pertussis infection, and its beneficial preventive and therapeutic effects on suppressing SARS-CoV-2-related lung damage have been revealed by several studies [90,91,92].